Comparative Pharmacology
Head-to-head clinical analysis: LONSURF versus PRALATREXATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LONSURF versus PRALATREXATE.
LONSURF vs PRALATREXATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LONSURF (trifluridine and tipiracil) is a combination of the thymidine-based nucleoside analogue trifluridine and the thymidine phosphorylase inhibitor tipiracil. Trifluridine incorporates into DNA and inhibits cell proliferation, while tipiracil increases trifluridine exposure by inhibiting its degradation by thymidine phosphorylase.
Folate analogue metabolic inhibitor that competitively inhibits dihydrofolate reductase (DHFR), disrupting DNA synthesis and cell proliferation.
Adults: 35 mg/m2 orally twice daily on days 1-5 and 8-12 of each 28-day cycle.
30 mg/m2 intravenously over 3-5 minutes on days 1, 8, and 15 of a 28-day cycle.
None Documented
None Documented
Clinical Note
moderatePralatrexate + Digoxin
"Pralatrexate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderatePralatrexate + Digitoxin
"Pralatrexate may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderatePralatrexate + Deslanoside
"Pralatrexate may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderatePralatrexate + Acetyldigitoxin
"Pralatrexate may decrease the cardiotoxic activities of Acetyldigitoxin."
Trifluridine: terminal half-life approximately 1.4-2.1 hours; tipiracil: terminal half-life approximately 2-3 hours. Clinical context: short half-lives necessitate twice-daily dosing on Days 1-5 and 8-12 of a 28-day cycle.
Terminal elimination half-life is approximately 12–19 hours in patients with normal renal function, supporting a weekly dosing interval.
Primarily renal: tipiracil is excreted unchanged in urine (approximately 50% of dose); trifluridine is eliminated via metabolism and renal excretion (as metabolites and unchanged drug). Fecal elimination accounts for <3% of total clearance.
Renal excretion accounts for approximately 70-80% of the administered dose as unchanged drug; biliary/fecal elimination is minimal (<10%).
Category C
Category C
Antineoplastic
Antineoplastic